XML 64 R49.htm IDEA: XBRL DOCUMENT
v3.22.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | $ 12,784 | $ 11,673 | $ 11,362
Renal Care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 3,900 | 3,757 | 3,639
Medication Delivery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 2,880 | 2,691 | 2,739
Pharmaceuticals |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 2,291 | 2,098 | 2,119
Clinical Nutrition |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 964 | 910 | 860
Advanced Surgery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 977 | 886 | 875
Acute Therapies |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 782 | 740 | 535
BioPharma Solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 669 | 486 | 469
Patient support systems |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 115 | 0 | 0
Front line care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 70 | 0 | 0
Surgical solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 27 | 0 | 0
Other |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 109 | 105 | 126
U.S. |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 5,180 | 4,878 | 4,826
U.S. | Renal Care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 890 | 848 | 791
U.S. | Medication Delivery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 1,859 | 1,738 | 1,762
U.S. | Pharmaceuticals |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 753 | 849 | 904
U.S. | Clinical Nutrition |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 343 | 330 | 308
U.S. | Advanced Surgery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 545 | 516 | 533
U.S. | Acute Therapies |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 287 | 286 | 184
U.S. | BioPharma Solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 273 | 234 | 257
U.S. | Patient support systems |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 86 | 0 | 0
U.S. | Front line care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 51 | 0 | 0
U.S. | Surgical solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 12 | 0 | 0
U.S. | Other |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 81 | 77 | 87
International |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 7,604 | 6,795 | 6,536
International | Renal Care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 3,010 | 2,909 | 2,848
International | Medication Delivery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 1,021 | 953 | 977
International | Pharmaceuticals |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 1,538 | 1,249 | 1,215
International | Clinical Nutrition |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 621 | 580 | 552
International | Advanced Surgery |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 432 | 370 | 342
International | Acute Therapies |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 495 | 454 | 351
International | BioPharma Solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 396 | 252 | 212
International | Patient support systems |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 29 | 0 | 0
International | Front line care |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 19 | 0 | 0
International | Surgical solutions |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | 15 | 0 | 0
International | Other |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |
Net sales | $ 28 | $ 28 | $ 39

X
- Definition Summary of significant accounting policies. + References No definition available. + Details
Name: | bax_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | bax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bax_RenalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_MedicationDeliveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_ClinicalNutritionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AcuteTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_BioPharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PatientSupportSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_SurgicalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_OtherProductOrServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |